Thomas Castellano
Director of Finance/CFO bij ABZENA PLC
Vermogen: 708 165 $ op 31-03-2024
Profiel
Momenteel is Thomas P. Castellano Global Vice President-Operational Finance bij Catalent, Inc. Hij zit ook in de raad van bestuur van Catalent France Beinheim SA. De heer Castellano behaalde een doctoraatsdiploma en een MBA aan de Seton Hall University.
Bekende belangen in openbare bedrijven
| Onderneming | Datum | Aantal aandelen | Totale waarde | Waarderingsdatum |
|---|---|---|---|---|
CATALENT INC
0.01% | 04-12-2023 | 12 545 ( 0.01% ) | 708 165 $ | 31-03-2024 |
Actieve functies van Thomas Castellano
| Bedrijven | Functie | Begin |
|---|---|---|
| ABZENA PLC | Director of Finance/CFO | 05-06-2023 |
Catalent France Beinheim SA
 Catalent France Beinheim SA Pharmaceuticals: MajorHealth Technology Catalent France Beinheim SA is engaged in softgel development and manufacturing operations. It offers formulation development and manufacturing services for controlled substances, highly potent compounds, and hormones. The firm’s technologies include optiform® solution suite, optigel™ bio, and rp scherer softgel technology. The company was founded on May 3, 1965 and is headquartered in Beinheim, France. | Director/Board Member | - |
| Catalent Belgium Holding SA | Director/Board Member | 05-08-2021 |
Eerdere bekende functies van Thomas Castellano
| Bedrijven | Functie | Einde |
|---|---|---|
| CATALENT, INC. | Director of Finance/CFO | 13-04-2023 |
Opleiding van Thomas Castellano
| Seton Hall University | Masters Business Admin |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
| Beursgenoteerde bedrijven | 1 |
|---|---|
| CATALENT, INC. | Health Technology |
| Bedrijven in privébezit | 3 |
|---|---|
| Catalent Belgium Holding SA | |
Catalent France Beinheim SA
Catalent France Beinheim SA Pharmaceuticals: MajorHealth Technology Catalent France Beinheim SA is engaged in softgel development and manufacturing operations. It offers formulation development and manufacturing services for controlled substances, highly potent compounds, and hormones. The firm’s technologies include optiform® solution suite, optigel™ bio, and rp scherer softgel technology. The company was founded on May 3, 1965 and is headquartered in Beinheim, France. | Health Technology |
Abzena Ltd.
 Abzena Ltd. BiotechnologyHealth Technology Abzena Ltd. engages in the provision of proprietary technologies and complementary services to enable the development and manufacture of biopharmaceutical products. It offers antibody discover and candidate screening, immunology and immunogenicity assessment, antibody and protein engineering, bio conjugation, custom synthesis of cytotoxic payloads, reagents, and other small molecules, manufacture of payload linkers, development of manufacturing cell lines, and manufacture of biopharmaceuticals. The company was founded by Sunil Shaunak in 2001 and is headquartered in Cambridge, the United Kingdom. | Health Technology |
